结直肠癌肝转移灶在钆塞酸增强MRI多个时间点的强化与肝切除术后无病生存相关
回顾性研究纳入82例结直肠癌肝转移肝切除患者,在化疗前(TP1)和化疗后(TP2)两个时间点测量肝胆期T1信号强度并归一化至骨骼肌。TP1强化≥135和TP2强化≥15预测复发风险降低,但经多重检验校正后不显著;持续低强化肿瘤复发可能性高9倍。
要点
- 肝胆期强化阈值TP1≥135、TP2≥15与复发风险降低相关,但多重检验校正后不显著。
- 两个时间点持续低强化的肿瘤复发可能性高9倍。
- 强化变化与复发风险无关,多因素模型中含8项临床特征时强化与复发无关。
核心结论
- 结直肠癌肝转移灶在钆塞酸增强MRI肝胆期两个时间点的强化增加与肝切除术后无病生存改善相关,作者认为这一初步观察需进一步研究系列强化测量作为预后生物标志物。
研究设计与样本
- 回顾性研究,82例患者(48例男性,平均年龄59岁)共135次影像检查,TP1有58次、TP2有77次、53例患者有TP1+2两个时间点;测量单个最大肿瘤的肝胆期T1信号强度并归一化至骨骼肌。
关键影像表现/征象
- 肝胆期T1信号强度归一化至骨骼肌,在化疗前(TP1)和化疗后(TP2)两个时间点测量。
- 持续低强化的肿瘤复发可能性高9倍。
诊断标准与关键数值
- TP1强化≥135和TP2强化≥15分别预测复发风险降低(P < .05),但经多重检验校正后不显著(P = .33和.20)。
- 82例患者中58例复发,中位复发时间11.7个月。
临床应用与阅片要点
- 双时间点信号评估可能对接受肝切除的结直肠癌肝转移患者的临床结局提供信息。
局限性
- 原文为回顾性研究。
- TP1和TP2强化阈值预测复发风险降低在多重检验校正后不显著(P = .33和.20)。
- 包括8项临床特征的多因素模型中强化与复发无关(P > .05)。
- 作者指出这一初步观察需进一步研究系列强化测量作为预后生物标志物。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
OBJECTIVES: To investigate signal intensity of colorectal cancer liver metastases (CRLM) at hepatobiliary phase (HBP) gadoxetate-enhanced MRI at 2 time points pre- (TP1) and post- chemotherapy (TP2) and association with disease-free survival (DFS) in patients undergoing curative liver resection.
METHODS: Retrospective study was conducted. Single largest tumours were outlined and HBP T1 signal intensity was measured and normalized to skeletal muscle at TP1 and TP2. Enhancement thresholds were defined and risk groups at each TP and Kaplan-Meier survival curves were compared using the log-rank test. Univariate and multivariate association of enhancement and 8 clinical features with risk of recurrence were calculated using Cox proportional hazards.
RESULTS: 82 patients (48 male, mean age 59 years) underwent 135 imaging studies, 58 at TP1, 77 at TP2, and 53 patients at TP1 + 2. Of 82 patients, 58 recurred with a median time to recurrence of 11.7 months. Enhancement of ≥135 and ≥15 at TP1 and TP2, respectively, were predictive of reduced risk of recurrence (P < .05), although not when corrected for multiple testing (P = .33 and .20, respectively). Enhancement was not associated with recurrence in multivariate model including 8 clinical features (P > .05). Change in enhancement between TP was not associated with risk of recurrence; however, tumours that consistently exhibited low enhancement were 9 times more likely to recur.
CONCLUSIONS: Increased CRLM enhancement in the HBP following gadoxetic acid at 2 TPs is associated with improved DFS in patients undergoing liver resection. This initial observation warrants further investigation of serial enhancement measurements as prognostic biomarkers.
ADVANCES IN KNOWLEDGE: Dual-time point signal assessment may be informative for clinical outcomes in CRLM undergoing resection.
引用
- Shur J, Kafaei L, Riddell A, et al. Enhancement of colorectal cancer liver metastases with gadoxetate-enhanced MRI at multiple time points is associated with disease-free survival following hepatectomy. Br J Radiol. 2025. PMID: 40036307. doi:10.1093/bjr/tqaf040
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。